US Patent 10941210 Anti-PCSK9 antibodies
Patent 10941210 was granted and assigned to Regeneron Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10941210 Anti-PCSK9 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
